Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results and Provide a Status Update to Investors on February 16, 2016
February 11, 2016 06:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report...
Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
February 02, 2016 08:20 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will...
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
February 02, 2016 08:16 ET
|
Adaptimmune Therapeutics plc
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trialsCreates opportunity for up to eight combination studies LONDON, PHILADELPHIA...
Commence Bio Finalizes Corporate Identity Change From WibiWorks Therapeutics and Introduces New Website
January 04, 2016 14:54 ET
|
Commence Bio
SPARKS, MD--(Marketwired - January 04, 2016) - Reflecting the STaRT™ of something big in immunotherapy, Commence Bio, Inc. today announced the completion of its corporate name change transition...
Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
December 17, 2015 11:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications
October 12, 2015 07:00 ET
|
Pluri Inc.
HAIFA, Israel, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced it has expanded...
Connecticut Children's Medical Center and Harvard Apparatus Regenerative Technology Collaborate to Develop Bioengineered Pediatric Esophageal Solutions
August 10, 2015 10:46 ET
|
Connecticut Childrens Medical Center
HARTFORD, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Connecticut Children's Medical Center has entered into an agreement with Harvard Apparatus Regenerative Technology, Inc., (NASDAQ: HART), or HART, a...
Endonovo Therapeutics Signs Funding Agreement for $10 Million
February 10, 2014 09:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA--(Marketwired - Feb 10, 2014) - Endonovo Therapeutics, Inc. (OTCQB: HVPA) ("Endonovo" or the "Company") announced that it has signed a best efforts funding agreement with an...
Hanover Portfolio Acquisitions Changes Its Name to Endonovo Therapeutics
January 28, 2014 09:00 ET
|
Hanover Portfolio Acquisitions
LOS ANGELES, CA--(Marketwired - Jan 28, 2014) - Hanover Portfolio Acquisitions, (OTCQB: HVPA) has announced that it will now operate under the name Endonovo Therapeutics, effective immediately.
...
FDA Agreement on Mesoblast's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells
February 12, 2013 20:28 ET
|
Mesoblast
MELBOURNE, Australia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast...